These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16932670)

  • 1. Is abatacept an effective treatment for patients with RA who do not respond to other anti-TNF treatments?
    Taylor PC
    Nat Clin Pract Rheumatol; 2006 Mar; 2(3):128-9. PubMed ID: 16932670
    [No Abstract]   [Full Text] [Related]  

  • 2. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
    Genovese MC; Becker JC; Schiff M; Luggen M; Sherrer Y; Kremer J; Birbara C; Box J; Natarajan K; Nuamah I; Li T; Aranda R; Hagerty DT; Dougados M
    N Engl J Med; 2005 Sep; 353(11):1114-23. PubMed ID: 16162882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy.
    Genovese MC; Schiff M; Luggen M; Le Bars M; Aranda R; Elegbe A; Dougados M
    J Rheumatol; 2012 Aug; 39(8):1546-54. PubMed ID: 22798265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Insight: abatacept for the treatment of rheumatoid arthritis.
    Ruderman EM; Pope RM
    Nat Clin Pract Rheumatol; 2006 Dec; 2(12):654-60. PubMed ID: 17133250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abatacept use after failure of multiple biologic agents in patients with severe rheumatoid arthritis.
    Hazlewood GS; Barnabe C; Barr SG; Martin L
    J Clin Rheumatol; 2012 Dec; 18(8):416-8. PubMed ID: 23188208
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate.
    Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Yuan Y; Oster G
    Rheumatology (Oxford); 2008 Apr; 47(4):535-41. PubMed ID: 18356179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abatacept in biologic-naïve patients and TNF inadequate responders: clinical data in focus.
    Sherrer Y
    Curr Med Res Opin; 2008 Aug; 24(8):2283-94. PubMed ID: 18590608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abatacept in the treatment of rheumatoid arthritis.
    Todd DJ; Costenbader KH; Weinblatt ME
    Int J Clin Pract; 2007 Mar; 61(3):494-500. PubMed ID: 17313619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
    Isaacs JD
    Expert Opin Biol Ther; 2009 Dec; 9(12):1463-75. PubMed ID: 19916731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists.
    Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Li T; Oster G
    J Rheumatol; 2008 Sep; 35(9):1745-53. PubMed ID: 18634164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
    Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
    Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective costimulation modulation with abatacept: a look at quality-of-life outcomes in patients with rheumatoid arthritis.
    Shergy WJ
    Semin Arthritis Rheum; 2009 Jun; 38(6):434-43. PubMed ID: 18538830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
    Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A
    Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom.
    Guyot P; Taylor PC; Christensen R; Pericleous L; Drost P; Eijgelshoven I; Bergman G; Lebmeier M
    J Rheumatol; 2012 Jun; 39(6):1198-206. PubMed ID: 22505698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fusion protein abatacept. Remission in every 5th TNF-alpha refractory patient].
    MMW Fortschr Med; 2008 Jun; 150(26-27):56-7. PubMed ID: 18683309
    [No Abstract]   [Full Text] [Related]  

  • 16. Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade.
    Manadan AM; Block JA
    Am J Ther; 2008; 15(1):53-8. PubMed ID: 18223354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of disease activity assessments in patients with rheumatoid arthritis and an inadequate response to anti-TNF therapy: analyses of abatacept clinical trial data.
    Dougados M; Wells G; Schmidely N; Le Bars M; van Riel P; Aletaha D; Schiff M; Smolen J
    Clin Exp Rheumatol; 2010; 28(2):258-60. PubMed ID: 20483050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation into the impact of abatacept on sleep quality in patients with rheumatoid arthritis, and the validity of the MOS-Sleep questionnaire Sleep Disturbance Scale.
    Wells G; Li T; Tugwell P
    Ann Rheum Dis; 2010 Oct; 69(10):1768-73. PubMed ID: 20610444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative efficacies: antimalarials to abatacept - the choice is ours.
    Russell AS
    J Rheumatol Suppl; 2009 Jun; 82():17-24. PubMed ID: 19509326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proposed severity and response criteria for Routine Assessment of Patient Index Data (RAPID3): results for categories of disease activity and response criteria in abatacept clinical trials.
    Pincus T; Hines P; Bergman MJ; Yazici Y; Rosenblatt LC; MacLean R
    J Rheumatol; 2011 Dec; 38(12):2565-71. PubMed ID: 22089467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.